Cost Effectiveness and Clinical Utility of Cell Saver Use for Two to Three Level Lumbar Fusions
This study is not yet open for participant recruitment.
Verified October 2011 by Norton Leatherman Spine Center
Sponsor:
Norton Leatherman Spine Center
Information provided by (Responsible Party):
Norton Leatherman Spine Center
ClinicalTrials.gov Identifier:
NCT01453309
First received: October 10, 2011
Last updated: October 14, 2011
Last verified: October 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the cost-effectiveness of using a cell saver for 2 to 3 level lumbar fusions. A secondary objective is to determine if there will be a decrease in the number of allogenic blood transfusions when a cell saver is used intraoperatively. Another secondary objective is to determine incidence of complications associated with cell saver use and transfusions.
| Condition | Intervention |
|---|---|
|
Low Back Pain Unresponsive to Non-surgical Care |
Procedure: Cell Saver Procedure: No Cell Saver |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Cost Effectiveness and Clinical Utility of Cell Saver Use for Two to Three Level Lumbar Fusions |
Resource links provided by NLM:
Further study details as provided by Norton Leatherman Spine Center:
Primary Outcome Measures:
- Volume of blood transfused [ Time Frame: Hospitalization, range of 3 to 14 days ] [ Designated as safety issue: No ]The total volume of blood and blood products transfused during surgery an during hospitalization will be determined
Secondary Outcome Measures:
- Immediate post-op Hematocrit level [ Time Frame: Post-operative, range of 1 to 14 days ] [ Designated as safety issue: No ]Immediate post-op Hematocrit level
- Immediate post-op Hemoglobin level [ Time Frame: Post-operative, range of 1 to 14 days ] [ Designated as safety issue: No ]Immediate post-op Hemoglobin level
| Estimated Enrollment: | 240 |
| Study Start Date: | October 2011 |
| Estimated Study Completion Date: | October 2013 |
| Estimated Primary Completion Date: | October 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Cell Saver
Patients will have the use of a cell-saver during surgery
|
Procedure: Cell Saver
Cell Savers are used intraoperatively to decrease the risk of transfusion due to surgical blood loss. Blood collected from the operative field is anticoagulated, filtered, and stored in a reservoir. Once a set volume of blood has been collected in the reservoir, the blood is separated into its red blood cell and plasma components by use of a centrifuge. Red blood cells are washed with a crystalloid solution and then reinfused into the patient.
|
|
Placebo Comparator: No Cell saver
Patient will not have cell saver available during surgery.
|
Procedure: No Cell Saver
Cell Saver will not be available during surgery
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- At least 18 years of age at time of enrollment
- Signed informed consent
- Requires fusion of 2 to 3 levels from L1-S1 for degenerative lumbar disorders
Exclusion Criteria:
- Spinal trauma/fracture/malignancy
- Infection as an indication for surgery
- Pregnant or nursing women
- Prisoners
- Institutionalized in a non-voluntary and/or dependent residence (including hospitals, group homes, etc.), who may not be competent to give informed consent.
- Inability to speak or understand English
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01453309
Contacts
| Contact: Leah Y Carreon, MD, MSc | 502 992 0488 ext 139 | leah.carreon@nortonhealthcare.org |
| Contact: Kelly R Bratcher, RN | 502 992 0488 ext 131 | kelly.bratcher2@nortonhealthcare.org |
Locations
| United States, Kentucky | |
| Norton Leatherman Spine Center | Not yet recruiting |
| Louisville, Kentucky, United States, 40202 | |
| Contact 502-744-0468 | |
| Principal Investigator: Mladen Djurasovic, MD | |
| Sub-Investigator: Steven D Glassman, MD | |
| Sub-Investigator: John R Dimar, MD | |
| Sub-Investigator: Rolando M Puno, MD | |
| Sub-Investigator: Mitchell J Campbell, MD | |
| Sub-Investigator: Charles H Crawford III, MD | |
| Sub-Investigator: R. Kirk Owens, MD | |
| Sub-Investigator: Leah Y Carreon, MD. MSc | |
Sponsors and Collaborators
Norton Leatherman Spine Center
Investigators
| Principal Investigator: | Mladen Djurasovic, MD | Norton Leatherman Spine Center |
More Information
No publications provided
| Responsible Party: | Norton Leatherman Spine Center |
| ClinicalTrials.gov Identifier: | NCT01453309 History of Changes |
| Other Study ID Numbers: | 11-N0216 |
| Study First Received: | October 10, 2011 |
| Last Updated: | October 14, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Norton Leatherman Spine Center:
|
lumbar fusion transfusion cell-saver cost-effectiveness |
Additional relevant MeSH terms:
|
Back Pain Low Back Pain Pain |
Neurologic Manifestations Nervous System Diseases Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013